Pfizer
Legal Engagements Amid Scientific Advancements: Alnylam’s Ongoing Interplay with Moderna
In the intricate choreography of the biopharmaceutical world, where innovation and intellectual property intertwine, a dramatic legal ballet unfolds. Alnylam, ...
Exploring Real-World Anticoagulant Transitions: Insights Unveiled at the European Society of Cardiology (ESC) Congress 2023
Amidst the vivid tapestry of medical advancements, a pivotal revelation has emerged from the collaborative efforts of the Bristol Myers ...
EC Approves Pfizer’s Abrysvo, Only RSV vaccine in EU for adults and infants
Pfizer has just received approval from the European Commission (EC) for its groundbreaking vaccine, Abrysvo. This vaccine, targeting the respiratory ...
Pfizer’s Approach to GBS Vaccine Approval Hinges on Immunogenicity Study
Amid the complexities of conducting an efficacy study for a group B streptococcus (GBS) vaccine, Pfizer’s lead vaccine executive is ...
Pfizer’s Abrysvo Achieves Landmark as First Maternal RSV Vaccine to Safeguard Newborns
Pfizer’s Abrysvo has achieved a groundbreaking milestone by becoming the first vaccine to safeguard newborns against respiratory syncytial virus (RSV) ...
Diversifying Strategies as Vaccine Demand Shifts: COVID-19 Vaccine Manufacturers Anticipate Fall Inoculation Season
Amidst a challenging environment of declining demand for COVID-19 vaccines, producers are eagerly awaiting the upcoming fall inoculation season as ...
Seagen’s Tukysa Demonstrates Trial Victory in Breast Cancer, Amplifying Roche’s Kadcyla and Significance in Light of Pfizer’s $43B Acquisition
In a strategic move, Pfizer has announced a hefty investment of $43 billion to acquire Seagen, with a keen focus ...
GSK’s Arexvy Takes Lead in RSV Vaccine Race, Now Accessible at Leading US Pharmacies
In the competitive landscape of the respiratory syncytial virus (RSV) vaccine market, GlaxoSmithKline (GSK) stands out with its well-timed strides. ...
COVID-19 Vaccine Makers Prepare for Private-Market Launches Amid Evolving Variants
Following a decline in demand for COVID-19 vaccines, prominent biopharmaceutical companies are gearing up for private-market launches this upcoming fall. ...
Pfizer’s Elrexfio Gets FDA Nod, Ignites Showdown with J&J in Multiple Myeloma Arena
Pfizer’s latest BCMA-targeted drug, Elrexfio (elranatamab), has gained FDA approval for treating multiple myeloma patients who have undergone at least ...
How Pfizer Defends Its Heart Drug Vyndamax from Generics
Just within four years of introducing their premium heart medication Vyndamax, Pfizer finds itself embroiled in a patent defense battle ...
Twitter and BioNTech under fire for evading COVID-19 vaccine questions
The regulatory organization overseeing the German communications sector has accused BioNTech of attempting to evade a public discussion regarding vaccine ...
Daiichi Sankyo to Dominate Antibody-Drug Conjugates Market by 2029
Daiichi has successfully established ADCs (Antibody-Drug Conjugates) as a significant therapeutic approach, overcoming previous years of underwhelming results. Even though ...
Tornado Wreaks Havoc on Pfizer’s Rocky Mount Plant, Causes Drug Shortages
Amid concerns of potential supply shortages of critical hospital drugs, Pfizer has taken precautionary measures in response to the tornado ...
GSK files a patent infringement lawsuit against Pfizer as the RSV vaccination war begins
In the latest vaccine showdown, GSK and Pfizer are engaged in a legal battle over patent infringement claims. GSK alleges ...
As COVID revenues fall short of expectations, once-flying Pfizer considers cost-cutting measures
As the revenues from COVID-19 products fluctuate, mostly experiencing a decline, Pfizer is now considering implementing cost-cutting measures. During a ...
Pfizer reveals executive leadership to advance its oncology R&D strategy
Source – Pfizer Pfizer has unveiled significant executive leadership changes aimed at advancing its commitment to research and development of ...
Less than anticipated supply impact from Pfizer’s tornado-damaged factory
The FDA has addressed the impact of the recent devastating tornado that hit Pfizer’s Rocky Mount facility in North Carolina. ...
Pfizer’s North Carolina Facility Hit by Tornado, Raising Concerns About US Medication Supply
A massive sterile injectables facility, considered one of the world’s largest, has fallen victim to a devastating natural disaster. On ...
Pfizer Unveils Promising GBS Maternal Vaccine in New England Journal of Medicine
Source – Pfizer On July 19, Pfizer released promising data from a Phase II study of their GBS6 vaccine candidate, ...
Pfizer and Flagship sign a $7 billion strategic level R&D agreement
Source – Pfizer Pfizer has formed a significant partnership with venture capital firm Flagship Pioneering, worth up to $7 billion, ...
In its COVID-19 vaccination lawsuits against Pfizer and BioNTech, CureVac makes further claims under the patent statute
Source – CureVac CureVac is intensifying its patent battle over COVID-19 vaccines by asserting additional claims against Pfizer and BioNTech ...
Moderna Files Two New Patent Lawsuits Against mRNA Competitors Pfizer and BioNTech
In the ongoing patent disputes surrounding COVID-19 vaccines, Moderna has expanded its legal battle against Pfizer and BioNTech by filing ...
After extending its Pfizer collaboration, Samsung Biologics signs a $391M manufacturing agreement with Novartis
Shortly after finalizing two deals worth $897 million with Pfizer, Samsung Biologics has expanded its partnership with Novartis, adding hundreds ...
Pediatric Growth Hormone Deficiency Long-Acting Once-Weekly Treatment NGENLA by Pfizer Receives FDA Approval
Source – Pfizer On 29 June 2023, Pfizer and OPKO Health jointly announced that the US Food and Drug Administration ...
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
Source – Pfizer On 28 June 2023, Pfizer announced that the US Food and Drug Administration (FDA) and the European ...
Pfizer Shares Progress of Clinical Development Program for GLP-1-RA in Adults with Obesity and Type II Diabetes Mellitus
Source – Pfizer On June 26, 2023, Pfizer Provides Update on Clinical Development Program for GLP-1-RA in Obesity and Type ...
FDA Grants Approval to Pfizer’s LITFULO (Ritlecitinib) for Severe Alopecia Areata in Adults and Adolescents
Source: Pfizer Pfizer announced on June 23, 2023, that the U.S. Food and Drug Administration (FDA) has granted approval to ...
CDC panel supports this year’s RSV vaccinations from GSK and Pfizer
If the Centres for Disease Control and Prevention (CDC) heed the counsel of professional advisers, adults in the US 60 ...
In a migraine head-to-head matchup, Pfizer’s Nurtec defeats Eli Lilly’s Emgality
Source – PR Newswire In a side-by-side comparison, Emgality did not outperform Pfizer’s Nurtec in preventing episodic migraines, Lilly said ...
